The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state laws. Direct dispensing enables physicians to more comprehensively manage their patients’ medical and therapeutic needs, which can facilitate quicker access to drugs and improve compliance. However, according to 2016 Decision Resources Group research,MCOs are concerned about this trend because it diverts prescriptions from their or their pharmacy benefit manager’s contracted specialty pharmacies and provides an additional revenue stream for the oncology practice. New 2017 data and analysis shed further light on the trend. Understanding physician dispensing and its effect on payer reimbursement and oncologists’ prescribing habits is vital to creating a sound market access strategy for drugs to treat renal cell carcinoma and other cancers with oral options.


  • How common is it for oncologists to dispense oral RCC drugs from within their practices or by using in-house dispensing pharmacies?
  • For what reasons would physicians want to bypass MCO-directed pharmacies and use a provider-owned pharmacy or dispense from their offices?
  • How do MCOs view and react to in-office dispensing by physicians, and how does this dynamic affect physician reimbursement?
  • Are oncologists more likely to choose oral RCC therapies if they can stock and dispense them instead of going through a payer’s specialty pharmacy?


Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Table of contents

  • Renal Cell Carcinoma - Access & Reimbursement - Detailed, Expanded Analysis: Implications Of Physician Dispensing Of Oral Oncolytics For Renal Cell Carcinoma (US)

Author(s): Chris Lewis

Chris Lewis serves as primary research manager, U.S. Access and Reimbursement, with responsibility for coordination, content review and content generation of the market access and reimbursement insights at DRG. Content is based on online surveys of managed care organizations and physicians and expert analysis of reimbursement and prescribing patterns of key therapies treating various disease states.

Lewis was an analyst/senior analyst for the group’s HealthLeaders-InterStudy subsidiary for eight years, specializing in the managed care and pharmacy benefit management industries. Throughout her tenure, she has produced the Health Plan Analysis reports for California, New York, New Jersey, Connecticut, and Pennsylvania and authored DRG’s series of pharmacy benefit manager profiles. She has also conducted numerous webinars for the group. She is a seasoned journalist with a B.A. in communications from California State University, Sacramento.

Related Reports

Renal Cell Carcinoma - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (US) 2020

This report is available to find out more click the link and fill out the form to get more details.

View Details

Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (US)

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angi...

View Details

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across the major mature pharmace...

View Details